Legis Daily

FORWARD Act of 2021

USA117th CongressHR-5566| House 
| Updated: 10/13/2021
Kevin McCarthy

Kevin McCarthy

Republican Representative

California

Cosponsors (4)
David Schweikert (Republican)Tom O'Halleran (Democratic)Karen Bass (Democratic)Greg Stanton (Democratic)

Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2021 or the FORWARD Act of 2021 This bill establishes programs to support research on endemic fungal diseases and the development of antifungal drugs, with a particular focus on Valley Fever. Endemic fungal diseases are fungal infections that tend to occur in specific geographic areas and affect older adults and other at-risk populations. Specifically, the bill establishes the Endemic Fungal Disease Working Group to review, coordinate, and make recommendations about the Department of Health and Human Services' efforts to address endemic fungal diseases. The working group is comprised of experts from both relevant federal agencies and the private sector. In addition, the National Institutes of Health must continue its support for research on endemic fungal diseases. Furthermore, the Food and Drug Administration must issue guidance for entities seeking approval for therapies, diagnostics, and vaccines to prevent and treat Valley Fever. Additionally, the bill provides for the use of priority reviews and other fast-track procedures to incentivize and expedite development and approval of these medical products. The bill also requires the Biomedical Advanced Research and Development Authority to implement the Combating Antimicrobial Resistance Biopharmaceutical Accelerator Program to reduce and prevent antimicrobial resistance.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-6713
FORWARD Act

Bill from Previous Congress

HR 116-2858
FORWARD Act of 2019
Oct 12, 2021
Introduced in House
Oct 12, 2021
Referred to the House Committee on Energy and Commerce.
Oct 13, 2021
Referred to the Subcommittee on Health.
Jan 13, 2022

Latest Companion Bill Action

S 117-3498
Introduced in Senate
  • Bill from Previous Congress

    HR 116-6713
    FORWARD Act


  • Bill from Previous Congress

    HR 116-2858
    FORWARD Act of 2019


  • October 12, 2021
    Introduced in House


  • October 12, 2021
    Referred to the House Committee on Energy and Commerce.


  • October 13, 2021
    Referred to the Subcommittee on Health.


  • January 13, 2022

    Latest Companion Bill Action

    S 117-3498
    Introduced in Senate

Health

Related Bills

  • S 117-3498: FORWARD Act of 2022
Advisory bodiesCardiovascular and respiratory healthCongressional oversightDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationDrug therapyEmergency medical services and trauma careExecutive agency funding and structureGovernment information and archivesHealth programs administration and fundingHealth promotion and preventive careImmunology and vaccinationInfectious and parasitic diseasesLicensing and registrationsMedical researchMedical tests and diagnostic methodsResearch administration and funding

FORWARD Act of 2021

USA117th CongressHR-5566| House 
| Updated: 10/13/2021
Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2021 or the FORWARD Act of 2021 This bill establishes programs to support research on endemic fungal diseases and the development of antifungal drugs, with a particular focus on Valley Fever. Endemic fungal diseases are fungal infections that tend to occur in specific geographic areas and affect older adults and other at-risk populations. Specifically, the bill establishes the Endemic Fungal Disease Working Group to review, coordinate, and make recommendations about the Department of Health and Human Services' efforts to address endemic fungal diseases. The working group is comprised of experts from both relevant federal agencies and the private sector. In addition, the National Institutes of Health must continue its support for research on endemic fungal diseases. Furthermore, the Food and Drug Administration must issue guidance for entities seeking approval for therapies, diagnostics, and vaccines to prevent and treat Valley Fever. Additionally, the bill provides for the use of priority reviews and other fast-track procedures to incentivize and expedite development and approval of these medical products. The bill also requires the Biomedical Advanced Research and Development Authority to implement the Combating Antimicrobial Resistance Biopharmaceutical Accelerator Program to reduce and prevent antimicrobial resistance.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-6713
FORWARD Act

Bill from Previous Congress

HR 116-2858
FORWARD Act of 2019
Oct 12, 2021
Introduced in House
Oct 12, 2021
Referred to the House Committee on Energy and Commerce.
Oct 13, 2021
Referred to the Subcommittee on Health.
Jan 13, 2022

Latest Companion Bill Action

S 117-3498
Introduced in Senate
  • Bill from Previous Congress

    HR 116-6713
    FORWARD Act


  • Bill from Previous Congress

    HR 116-2858
    FORWARD Act of 2019


  • October 12, 2021
    Introduced in House


  • October 12, 2021
    Referred to the House Committee on Energy and Commerce.


  • October 13, 2021
    Referred to the Subcommittee on Health.


  • January 13, 2022

    Latest Companion Bill Action

    S 117-3498
    Introduced in Senate
Kevin McCarthy

Kevin McCarthy

Republican Representative

California

Cosponsors (4)
David Schweikert (Republican)Tom O'Halleran (Democratic)Karen Bass (Democratic)Greg Stanton (Democratic)

Health Subcommittee, Energy and Commerce Committee

Health

Related Bills

  • S 117-3498: FORWARD Act of 2022
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Advisory bodiesCardiovascular and respiratory healthCongressional oversightDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationDrug therapyEmergency medical services and trauma careExecutive agency funding and structureGovernment information and archivesHealth programs administration and fundingHealth promotion and preventive careImmunology and vaccinationInfectious and parasitic diseasesLicensing and registrationsMedical researchMedical tests and diagnostic methodsResearch administration and funding